Though chemotherapy is currently the most common course of treatment for esophageal carcinoma, some randomized clinical trials are showing potential for a wider range of patient options according to Steven Krasnow, MD.
“The changing epidemiology and biology of esophagus cancer presents some selected treatment advances,” Krasnow said. “Some trials have set new care standards and some advances have demonstrated improved overall survival.”
